Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2003
05/14/2003CN1108294C Piperazine-2,5-dione derivatives as modulators of multidrug resistance
05/14/2003CN1108291C Method for preparing substituted perhydroisoindole
05/14/2003CN1108290C Urea derivatives
05/14/2003CN1108289C Difluoroprostaglundin derivatives and their use
05/14/2003CN1108157C Gel composition for treating pulmonary tuberculosis cavity difficult to cure it
05/14/2003CN1108156C Long-acting analgesic used mainly for operational cut and traumatic wound
05/14/2003CN1108155C Preparation absorbed through skin, containing woluke kinds of medicine
05/14/2003CN1108154C Drug composition for curing gynaecological vaginitis
05/14/2003CN1108153C Oral compositions containing ondansetron
05/14/2003CN1108152C Rapamycin formulations for oral administration
05/14/2003CN1108101C Povidone iodine solution of multi-element dispersion medium
05/13/2003US6564152 Pharmacophore models for, methods of screening for, and identification of the cytochrome P-450 inhibitory potency of neurokinin-1 receptor antagonists
05/13/2003US6563009 Vasodilator cannabinoid analogs
05/13/2003US6563008 Biphenyl compounds and their use as oestrogenic agents
05/13/2003US6562988 16-HETE (16-hydroxyeicosatetraenoic acid) analogues such as the methanesulfonamide ester (-CO-NH-SO2-CH3); inhibiting neutrophil adhesion and neutrophil aggregation; treating stroke, inflammatory diseases
05/13/2003US6562980 Method for producing 5-aryloxymethyl-2-oxazolidinones
05/13/2003US6562978 N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS
05/13/2003US6562976 Such as methyl-2-cyclopentyl-4-(4-fluorophenyl)-5-oxo-7,7-dimethyl-1,4,5,6,7,8 -hexahydroquinoline-3-carboxylate for treatment of arteriosclerosis and dyslipidaemias; condensation
05/13/2003US6562963 Coupling using organosilicon compound
05/13/2003US6562960 Oligonucleotide analogues
05/13/2003US6562873 Containing oxy-chloro components including chlorine dioxide, hypochlorite, perchlorate or chlorite components
05/13/2003US6562872 Emulsion of perfluoroorganic compounds for medical purposes, a process for the preparation thereof and methods for treating and preventing diseases with the use thereof
05/13/2003US6562871 Dry granulation of pharmaceutical formulation comprising mexiletine
05/13/2003US6562868 Method of treating female sexual dysfunction, comprising administering to a human a therapeutically effective and physiologically acceptable amount of a prostaglandin selected from the group consisting of 19-hydroxy-PGE2,
05/13/2003US6562867 Halogenated 2-phenyl-1,2-ethanediol monocarbamate derivatives
05/13/2003US6562866 A method for treating or preventing an elevated blood lipid level-related disease in a mammal, which comprises administering thereto an effective amount of rutin, quercetin or a mixture thereof.
05/13/2003US6562865 Composition comprising a tramadol material and an anticonvulsant drug
05/13/2003US6562864 Catechin multimers as therapeutic drug delivery agents
05/13/2003US6562863 Partially purified cocoa extracts containing cocoa polyphenols
05/13/2003US6562862 Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
05/13/2003US6562861 Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
05/13/2003US6562860 Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
05/13/2003US6562859 Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation
05/13/2003US6562858 Administering as a melatonin receptor agonist 5-methoxycarbonylamino-N-acetyltryptamine or its analogs; bipolar disease, anxiety
05/13/2003US6562857 Cyanopyrroles
05/13/2003US6562855 Comprises a formulation. The formulation comprises an NMDA antagonist and an alpha-2 adrenergic agonist. In a preferred aspect, there is provided an improved anaesthetic comprising an NMDA antagonist and an alpha-2 adrenergic agonist.
05/13/2003US6562851 Antiinflammatory and antiasthmatic agents; inhibitors of alpha4 beta1 mediated cell adhesion
05/13/2003US6562849 Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc.
05/13/2003US6562847 Pyridyl ethers and thioethers as ligands for nicotinic acetylcholine receptor and its therapeutic application
05/13/2003US6562846 Bisarylimidazolyl fatty acid amide hydrolase inhibitors
05/13/2003US6562843 For treating disorders ameliorated by a reduction in TNF-alpha production and/or p38 activity, and are therefore useful for treating inflammatory disorders such as rheumatoid arthritis, as well as AIDS-related disorders
05/13/2003US6562839 6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both
05/13/2003US6562838 Providing subject suffering from a symptoms of cardiovascular disease and a purified enantiomer preparation of flosequinan; administering preparation to subject under conditions such that symptom is reduced
05/13/2003US6562837 Use of tetrahydroisoquinoline compounds for the treatment of septicemia
05/13/2003US6562836 Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes
05/13/2003US6562835 One morphinan selected from the group consisting of dextromethorphan, dextrorphan and at least one active agent selected from tricyclic antidepressants, antispasmodics, direct-acting bladder smooth muscle relaxants, and estrogens
05/13/2003US6562834 Combination comprising camptothecin and a stilbene derivative for the treatment of cancer
05/13/2003US6562831 Inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases
05/13/2003US6562830 Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
05/13/2003US6562829 Halofuginone can inhibit the pathological process of hepatic cirrhosis in vivo, possibly by inhibiting collagen type I synthesis
05/13/2003US6562828 Amidine compounds
05/13/2003US6562827 For the treatment of diseases in which increased calpain activity occurs such as neurodegenerative diseases or neuronal damage are caused by ischemia, trauma or mass hemorrhages
05/13/2003US6562826 To maintain human ranolazine plasma levels at therapeutic levels
05/13/2003US6562825 For treating inflammatory disease including asthma and allergic diseases, as well as autoimmune pathologies
05/13/2003US6562824 Dihydropyridine soft drugs, and related compositions and methods
05/13/2003US6562823 Inhibition of farnesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar
05/13/2003US6562821 For treating arthritis and related disorders, and for treating diseases associated with altered mitochondrial function
05/13/2003US6562820 Method for treatment and prevention of mastitis
05/13/2003US6562819 Compounds for inhibition of ceramide-mediated signal transduction
05/13/2003US6562817 Suppressants of the IgE production
05/13/2003US6562816 Alpha 7 nicotine acetylcholine receptor agonist anti-psychotic agent, with reduced side effects
05/13/2003US6562813 Aralkyl and aralkylidene heterocyclic lactams and imides
05/13/2003US6562811 Pyridine derivatives
05/13/2003US6562810 8-substituted-9H-1,3-dioxolo/4,5-h//2,3/benzodiazepine derivatives, as AMPA/kainate receptor inhibitors
05/13/2003US6562809 Contraction of coronary arteries may be mediated by its stimulation of the 5-HT1B (formerly 5-HT1D beta); compounds selective for a 5-HT1D receptor
05/13/2003US6562806 Pyrrolobenzodiazepines
05/13/2003US6562802 Anionic ethylene amine scavenger; and cationic, hydrophilic amine containing polymer like chitosan and derivatives, cationic polyethylenes, DEAE-4, and polyornithine
05/13/2003US6562796 Derivatives of polyene macrolides and preparation and use thereof
05/13/2003US6562795 Motilide compounds
05/13/2003US6562794 Cosmetic and dermatological formulations comprising flavonoids
05/13/2003US6562793 Antiallergic agent
05/13/2003US6562792 Hygromycin derivatives
05/13/2003US6562790 Administering a combination of natural hormones including human growth hormone with sufficient T3 thyroid supplement to maintain the body temperature of the subject at or above 97.6 degrees F. upon awakening and at 98.7 degrees F
05/13/2003US6562785 Antimicrobial agent permeabilizes bacterial but not non-bacterial cell and is sufficient to transiently permeabilize the bacteria; toxic agent is only toxic upon entry into the antibiotic resistant bacteria
05/13/2003US6562782 Oligocycloalkanoid compounds and methods of use
05/13/2003US6562781 Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
05/13/2003US6562613 Recombinant C-proteinase and processes, methods and uses thereof
05/13/2003US6562606 Methods and compositions for disrupting the epithelial barrier function
05/13/2003US6562593 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/13/2003US6562582 Removing preferential microorganism from sample; obtain sample, incubate with prophylactic agent, monitor sample for presence of microorganism
05/13/2003US6562564 Decreasing cell proliferation by decreasing levels of PP5
05/13/2003US6562392 Hard caramel product
05/13/2003US6562381 (+)-Cycloolivil as antioxidant obtained from natural source namely stereospermum personatum
05/13/2003US6562380 Methods for treating or reducing prediposition to breast cancer, pre-menstrual syndrome or symptoms associated with menopause by administration of phyto-estrogen
05/13/2003US6562378 Nutritional supplement for adolescents
05/13/2003US6562372 Tocotrienol-containing powder, a process for preparing it and a tablet comprising compressed said powder into a tablet form
05/13/2003US6562370 A combination of an estrogen and progestin for female hormoe replacement therapy, to provide contraception; minimizes skin damage, irritation or sensitization
05/13/2003US6562369 Administering drug to localized region of human patient's body surface in combination with hydroxide releasing agent applied to body surface
05/13/2003US6562368 Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
05/13/2003US6562367 Solvent free formulation; minimum thermal exposure; high bioavailability; sustained release
05/13/2003US6562365 Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction.
05/13/2003US6562364 Desmethylselegiline enantiomers and their use to treat drug withdrawal symptoms
05/13/2003US6562362 Copolymer of n-isopropylacrylamide and an ionic strength or pH sensitive monomer; nondegradable; side effects reduction
05/13/2003US6562360 Useful as skin disinfectants, surgical hand preparations, patient skin preparations and antimicrobial hand lotions
05/13/2003US6562355 Comixture of dextran sulfate/escin for treating skin redness/edema and/or sensitive skin
05/13/2003US6562353 Desquamation/epidermal renewal of the skin and/or combating skin aging
05/13/2003US6562336 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
05/13/2003US6562335 NK-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy
05/13/2003US6562333 Purified mammalian CTLA-8 antigens and related reagents
05/13/2003US6562330 Gelling polyacrylate with pendant zwitterionic groups and counterion component in body cavity; improving biocompatibi-lity; such as embolizing vein or packing aneurysm
1 ... 5472 5473 5474 5475 5476 5477 5478 5479 5480 5481 5482 5483 5484 5485 5486 5487 5488 5489 5490 5491 5492 ... 7860